MMU banner 1

All posts by Simon Carley

Simon Carley MB ChB, PGDip, DipIMC (RCS Ed), FRCS (Ed)(1998), FHEA, FAcadMed, FRCEM, MPhil, MD, PhD is Creator, Webmaster, owner and Editor in Chief of the St Emlyn’s blog and podcast. He is visiting Professor at Manchester Metropolitan University and a Consultant in adult and paediatric Emergency Medicine at Manchester Foundation Trust. He is co-founder of BestBets, St.Emlyns and the MSc in emergency medicine at Manchester Metropolitan University. He is an Education Associate with the General Medical Council and is an Associate Editor for the Emergency Medicine Journal. His research interests include diagnostics, MedEd, Major incidents & Evidence based Emergency Medicine. He is verified on twitter as @EMManchester

tocilizumab

JC: RECOVERY trial shows Tocilizumab effective for COVID19. St Emlyn’s

In arguably the most important therapeutic news of the pandemic since Dexamethasone, the RECOVERY trial investigators have revealed the initial results on the Tocilizumab arm of the trial showing a significant benefit. This short blog

JC: Canadian TIA risk score. St Emlyn’s

We see a lot of patients in the ED with a history of what sounds very much like a transient ischaemic event (TIA). By definition the patient will have had resolution of their symptoms/signs and

Oxygen targets in critical care: The HOT-ICU trial. St Emlyn’s

Oxygen targets in critically ill/injured patients has been something we’ve talked about on the blog before. In general the evidence to date has suggested that the routine prescription of oxygen to patients is unhelpful and

vaccines

Vaccines update January 2021: St Emlyn’s

Rick Body has once again put together a great COVID-19 podcast to update us on the latest vaccines roll out in the UK. Prof. Rick Body, Prof. Simon Carley, Prof. Pam Vallely, Prof. Paul Klapper

#FOAMed for academics: A primer. St Emlyn’s

This week I’m (virtually) attending the RCEM Research Engagement Day. This annual event combined an academic trainee day (14th) together with a more general day looking at research in a broader sense with lots of

JC: Lopinavir/Ritonavir in the treatment of COVID-19

We have been following the RECOVERY trial closely over the last few months. It’s the largest RCT of therapeutics for COVID-19 in the world and it’s already shown that hydroxychloroquine and azithromycin don’t work in

Risk stratification in the ED for COVID19 patients: The PRIEST study. St Emlyn’s

A core skill in emergency medicine is in the identification and classification of risk categories for the patients we see. For many conditions we have derived, validated and refined scoring systems over many years (for

COVID-19 testing

Understanding COVID-19 testing with Rick Body. St Emlyn’s

This week Simon and Rick got together to talk through the latest technologies, uses and performance of COVID-19 testing. We think it’s a really useful listen to understand the strengths and weaknesses of the various

JC: Convalescent plasma in COVID 19 patients.

This month the BMJ has published a trial on the use of convalescent plasma in the treatment of admitted patients with COVID-19 (the PLACID trial). Convalescent plasma therapy basically takes plasma, together with antibodies from

CODA Zero episodes now open access.

I’m not sure whether you have noticed, but the first two episodes of the CODA Zero program are now live on their website. If you did not already know, the CODA project is designed to